IOVAIovance Biotherapeutics, Inc.
What is the market doing?
No clear lean: in an uptrend, but heavily shorted (+14% of shares).
In an uptrend, above its rising 50- and 200-day averages. Price is +154% vs its 200-day average.
Heavily shorted, settled Sep 30, 2026, a few days of normal trading to cover. Down 26% since the previous count, down from 22.2% of shares outstanding three months ago.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How IOVA is trading
Iovance Biotherapeutics, Inc. is +529% over the past year while the S&P 500 is +16%: 513 points ahead of the market.
1-year return · S&P 500 +16%
- vs 200-day average
- +154%
vs 200-day average · a clear uptrend
- RSI (14)
- 50
RSI (14) · neutral
- Below its 52-week high
- 5.3%
Below its 52-week high
Details›
- Last close2026-10-23
- $14.08
- 1 monthS&P 500 −0.94%
- +30%
- 1 yearS&P 500 +16%
- +529%
- 5 yearsS&P 500 +86%
- −46%
- vs 50-day average$10.88
- +29%
- 52-week high
- $14.87
- 52-week low
- $1.81
- Annualised volatility
- 103%
| Year | Return |
|---|---|
| 2026 (year to date) | +416% |
| 2025 | −63% |
| 2024 | −9.0% |
| 2023 | +27% |
| 2022 | −67% |
| 2021 | −59% |
| 2020 | +68% |
| 2019 | +213% |
| 2018 | +11% |
| 2017 | +15% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 4 of 10 | +5.4% |
| Feb | 10 | 6 of 10 | +18% |
| Mar | 10 | 1 of 10 | −8.4% |
| Apr | 10 | 3 of 10 | −2.9% |
| May | 10 | 4 of 10 | −7.6% |
| Jun | 10 | 5 of 10 | +14% |
| Jul | 11 | 9 of 11 | +6.5% |
| Aug | 11 | 5 of 11 | +8.2% |
| Sep | 11 | 4 of 11 | +1.2% |
| Oct | 11 | 4 of 11 | −3.8% |
| Nov | 10 | 7 of 10 | +6.5% |
| Dec | 10 | 6 of 10 | +5.1% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.